All In Biotech

Drug Trial Radar · NCT07689240

Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma

Phase III Study of Adjuvant Pembrolizumab vs Active Surveillance After Nephrectomy in Patients With Non-Clear Cell Renal-Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 10, 2027

Primary completion

Jan 1, 2032

Study completion Jan 1, 2032

Sponsor

Sponsor type
NIH
First posted
Jul 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear cell renal cell cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after nephrectomy may be more effective than the usual active surveillance approach for improving time without disease in patients with non-clear cell renal cell cancer.

Conditions

  • Non-Clear Cell Renal Cell Carcinoma
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Bone ScanProcedure

    Undergo bone scan

  • Computed TomographyProcedure

    Undergo CT and PET/CT

  • Echocardiography TestProcedure

    Undergo ECHO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Patient ObservationOther

    Undergo active surveillance

  • PembrolizumabBiological

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival (DFS)Time frame: From randomization to first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first, assessed up to 10 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.